Press release
Uterine Leiomyoma (Uterine Fibroids) Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - Ogeda, Advance Biofactures Corp., Bayer, Myov
Uterine Leiomyoma (Uterine Fibroids) Pipeline
The treatment paradigm of Uterine Fibroids includes the use of simple pain relief medications, hormonal therapy, and surgery. As per DelveInsight, the Uterine Leiomyoma therapeutics market is anticipated to evolve in the coming years owing to the rise in the number of diagnosed prevalent cases, the improvement in the research and development activities, and the launch of the emerging pipeline therapies. The pipeline of Uterine Fibroids possesses potential key players, such as ObsEva, Myovant Sciences, and others.
"Uterine Leiomyoma (Uterine Fibroids) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Uterine Leiomyoma (Uterine Fibroids) Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Uterine Leiomyoma (Uterine Fibroids) Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Uterine Leiomyoma (Uterine Fibroids) Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uterine Leiomyoma (Uterine Fibroids) treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Uterine Leiomyoma (Uterine Fibroids) market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More About Key Developments in the Therapeutics Market:
https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Mechanism of Action (MOA) of the Emerging Therapies
- Collagenase replacements
- Progesterone receptor antagonists
- LHRH receptor antagonists
Route of Administration (ROA)
Uterine leiomyomata (Uterine Fibroids) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as -
- Oral
- Intravenous
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as -
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Uterine Leiomyoma (Uterine Fibroids) Therapeutics Analysis
Treatment options for uterine fibroids include over-the-counter (OTC) pain medications, iron supplements, birth control, Gonadotropin-releasing hormone (GnRH) agonists, and oral therapies. To further improve the treatment dynamics, globally, several major pharma and biotech giants are developing therapies for Uterine leiomyomata (Uterine Fibroids). Currently, Ogeda is leading the therapeutics market with its Uterine leiomyomata (Uterine Fibroids) drug candidates in the most advanced stage of clinical development.
Key Companies in the Uterine Leiomyoma (Uterine Fibroids) Therapeutics Market:
- Bayer HealthCare Pharmaceuticals
- Ogeda
- Treadwell Therapeutics
- Contex Therapeutics
- Repros Therapeutics
- Neurocrine Biosciences
And Many Others
Uterine leiomyomata (Uterine Fibroids) Drugs Covered in the Report Include:
- Fezolinetant: Ogeda
- EN3835: Advance Biofactures Corporation
- Vilaprisan or BAY1002670: Bayer
- Orgovyx (Relugolix, TAK-385): Myovant/Takeda
- Elagolix: AbbVie
- ObsEva in-licensed Yselty (Linzagolix, OBE2109): Kissei Pharmaceutical
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/uterine-leiomyoma-uterine-fibroids-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Uterine Leiomyoma (Uterine Fibroids) Current Treatment Patterns
4. Uterine Leiomyoma (Uterine Fibroids) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Uterine Leiomyoma (Uterine Fibroids) Late-Stage Products (Phase-III)
7. Uterine Leiomyoma (Uterine Fibroids) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Uterine Leiomyoma (Uterine Fibroids) Discontinued Products
13. Uterine Leiomyoma (Uterine Fibroids) Product Profiles
14. Uterine Leiomyoma (Uterine Fibroids) Key Companies
15. Uterine Leiomyoma (Uterine Fibroids) Key Products
16. Dormant and Discontinued Products
17. Uterine Leiomyoma (Uterine Fibroids) Unmet Needs
18. Uterine Leiomyoma (Uterine Fibroids) Future Perspectives
19. Uterine Leiomyoma (Uterine Fibroids) Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/uterine-leiomyoma-uterine-fibroids-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/uterine-leiomyoma-uterine-fibroids-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uterine Leiomyoma (Uterine Fibroids) Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Key Companies - Ogeda, Advance Biofactures Corp., Bayer, Myov here
News-ID: 2928333 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Uterine
Uterine Fibroids Symptoms
USA Fibroids Center is here to offer detailed information on https://www.usafibroidcenters.com/blog/uterine-fibroids-symptoms/ and help you discuss the best treatments for uterine fibroids at the clinic.
Find out the best Fibroid Treatment for you!
Treatments for uterine fibroids are accessed in women with problems related to them and show symptoms such as heavy menstrual bleeding, pain or pressure in the pelvis, or infertility and sterility.
…
Bharath Hospital Kottayam Offers Minimally Invasive Treatment for Uterine Fibroi …
Bharath Hospital Kottayam is excited introduce the latest advancement in women's healthcare - the Uterine Fibroid Embolization (UFE) treatment. Uterine fibroids are non-cancerous growths that form in the uterus. They are a common condition among women, especially those of reproductive age. These tumors can vary in size, from small growths to large masses that can distort the shape of the uterus. Although many women with uterine fibroids experience no symptoms,…
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Uterine Fibroids Treatment Market : Hysterectomy to Remain Most Preferred Uterin …
The market for uterine fibroids treatment market is fragmented in nature with a high number of players operating in it across the U.S., states a new market research report by Transparency Market Research. The estimated entry of new players and the increasing research and development activities are some of the key factors that are projected to strengthen the competitive scenario of the market throughout the forecast period. The leading players…
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018 - Research By Ma …
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers…
Uterine Fibroids Treatment Market: Rising Prevalence of Uterine Fibroids amongst …
The high prevalence of uterine fibroids across the U.S. has created a significant demand for uterine fibroid treatments across the countries. The growing public concern about the occurrence of uterine fibroids, which are also called uterine leiomyoma, have propelled the demand for treatments and solutions to alleviate the pain, excessive bleeding, and pelvic discomfort.
According to the report by Transparency Market Research, the U.S. uterine fibroid treatment market is anticipated to…
